Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study

BACKGROUND: Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs/bDMARDs) in combination with methotrexate (MTX) or as monotherapy. However, real-world data are scarce regarding e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayat, Sara, Tascilar, Koray, Bohr, Daniela, Krönke, Gerhard, Simon, David, Knitza, Johannes, Hartmann, Fabian, Schett, Georg, Kleyer, Arnd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680190/
https://www.ncbi.nlm.nih.gov/pubmed/36410777
http://dx.doi.org/10.1136/rmdopen-2022-002674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680190/
https://www.ncbi.nlm.nih.gov/pubmed/36410777
http://dx.doi.org/10.1136/rmdopen-2022-002674

Ejemplares similares